Register
Login:
Share:
Email Facebook Twitter

EXCLUSIVE: Aminex CEO says 'Institutions are delighted' with Zubair farm-out terms Watch Here

EXCLUSIVE: Aminex CEO says 'Institutions are delighted' with Zubair farm-out terms
EXCLUSIVE: InfraStrata continue to negotiate with major gas companies and institutional investors


Glaxosmithkline Share Price (GSK)



Share Price Information for Glaxosmithkline (GSK)


Share Price: 1,565.00Bid: 1,564.80Ask: 1,565.00Change: 6.80 (+0.44%)Riser - Glaxosmithkline
Spread: 0.20Spread as %: 0.01%Open: 1,556.00High: 1,567.80Low: 1,550.20Yesterday’s Close: 1,558.20

Glaxosmithkline Plc Ord 25P

Glaxosmithkline is listed in the FTSE 100, FTSE All-Share, FTSE 350, FTSE 350 High Yield
Glaxosmithkline is part of the Medicine and Biotech Research sector

Glaxosmithkline has a share of around 5% of the world's pharmaceutical market, aiming to tackle 3 of the 'priority' diseases identified by the World Health Organisation. The company employs around 96,500 people in over 100 countries. In 2010 they delivered 1.4 billion vaccine doses to 179 countries.





Share Price SpacerPrice
1565.00
Share Price SpacerBid
1564.80
Share Price SpacerAsk
1565.00
Share Price SpacerChange
0.44%6.80
Share Price SpacerVolume
4,052,148
Share Price SpacerOpen
1,556.00
Share Price SpacerHigh
1,567.80
Share Price SpacerLow
1,550.20
Share Price SpacerClose
1,558.20
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 4,959.87m £77,621.92m 1,500

52 Week High 1,632.00 52 Week High Date 21-JUL-2017
52 Week Low 1,236.40 52 Week Low Date 6-FEB-2018

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
9,358 1,528,706 1,854,654 49.841 31.40 80.00 5.11


London South East Users info for Glaxosmithkline


Users who watch GSK also watch: Lloyds, BP, Vodafone, Tesco, Barclays, Royal Bank of Scotland, HSBC, BT, National Grid, Aviva

Users who hold GSK also hold: Vodafone, BP, Lloyds, National Grid, Royal Dutch Shell B, Tesco, HSBC, Centrica, Aviva, BT


Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

17-Jul-18
16:13:23
1,564.80
207
Buy* 
1,564.60
1,564.80
3,239
Trade Type:
Automatic execution

17-Jul-18
16:13:23
1,564.80
351
Buy* 
1,564.60
1,564.80
5,492
Trade Type:
Automatic execution

17-Jul-18
16:13:23
1,564.80
49
Buy* 
1,564.60
1,564.80
766.75
Trade Type:
Automatic execution




View more Glaxosmithkline trades >>

Directors Deals for Glaxosmithkline (GSK)
Trade DateActionNotifierPriceCurrencyAmountHolding
01-Dec-17Exercise of option
Trade Notifier Information for GlaxoSmithKline
Simon Dingemans held the position of CFO at GlaxoSmithKline at the time of this trade.
 Simon Dingemans
1131GBX23817564623
09-Nov-17Buy
Trade Notifier Information for GlaxoSmithKline
Emma Walmsley held the position of CEO at GlaxoSmithKline at the time of this trade.
 Emma Walmsley
1364.18GBX1085883
09-Nov-17Buy
Trade Notifier Information for GlaxoSmithKline
Simon Dingemans held the position of CFO at GlaxoSmithKline at the time of this trade.
 Simon Dingemans
1364.18GBX917564376
View more Glaxosmithkline directors dealings >>


Pokerchips
Posts: 4,395
Opinion:No Opinion
Price:1,576.00
RE: Looking good
Fri 17:59
Bewareshadows,

Good move to take some profit....you cannot lose it once you have banked it....which I had traded PFC a few more times with that in mind LOL

This has gained on the back of sterling falling...and more BREXIT confusion could see this as a defensive ....the revenues here are fairly steady and I think in Q2 results Emma is going to really get stuck into more cost cutting and more efficiency drives and better pharma focus on profitability .....we wait and see on that one for the 25th July

I am happy to sit with the ebb and flow of PFC for now...the BOD and the teams know what they are doing

Good luck
Pokerchips
Posts: 4,395
Opinion:No Opinion
Price:1,576.00
RE: Looking good
Fri 17:51
" Who's talking about buying at 1750? of course the march to 1750 would be with sights on selling."

Hummmm.. well in order to get to 1750p you need buyers ...or have you not worked that side of the equation out ?
AvatarIII
Posts: 4
Opinion:No Opinion
Price:1,584.00
RE: Looking good
Fri 15:00
Who's talking about buying at 1750? of course the march to 1750 would be with sights on selling.
bewareshadows
Posts: 766
Opinion:Hold
Price:1,584.60
RE: Looking good
Fri 12:29
Hi Poker,

Another diversified PFC holder.

I've sold my holding here today at 1589. Not particularly worried about this share but it's been bouncing around between 1500 and 1580. Considering I was down on this for most of my time, decided to take some profit and hopefully buy in on the next drop to 1515.

Not saying it will and good luck to those holding for the 1700's, if it goes there great.
Pokerchips
Posts: 4,395
Opinion:No Opinion
Price:1,579.60
RE: Looking good
Fri 11:48
I wouldnt pay 1750p but I sure as hell would consider selling at 1750p

If you buy at 1750p then you obviously are looking for 1800p plus ....

The earnings would have to show a marked increase for that to seem fair value

The Novartis Consumer Healthcare buyout isnt really going to show in the earnings until Q3

..unless of course takeover speculation appeared... then 1750p is cheap i guess
View more share chat for Glaxosmithkline (GSK) >>




Glaxosmithkline Plc Ord 25P home pageWebsite: Glaxosmithkline Plc Ord 25P
Website Description: GlaxoSmithKline - Redirect



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.